Vous avez cherché: licensing (Espagnol - Danois)

«sanctions licensing unit
»sanctions licensing unit

ministry of industry and trade, licensing office
ministry of industry and trade, licensing office

reino unido import licensing branch (ilb)
det forenede kongerige

hungarian trade licensing office (magyar kereskedelmi engedélyezési hivatal)
hungarian trade licensing office (magyar kereskedelmi engedélyezési hivatal)

points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:

adjustment for multiplicity and related topics points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
adjustment for multiplicity and related topics points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:

choice of non-inferiority margin points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
choice of non- inferiority margin points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:

concept paper on the development of a cpmp points to consider on biostatistical/methodological issues arising from cpmp discussions on licensing applications: adjustment for baseline covariates adoptada en febrero de 2000
sendt til høring i december 2000

todas las solicitudes se valorarán con arreglo a las condiciones del reglamento sobre concesión de licencias para hidrocarburos de 1995 ("hydrocarbons licensing directive regulations 1995 (s.i. 1995 no.
alle ansøgninger vurderes i henhold til betingelserne i hydrocarbons licensing directive regulations 1995 (s.i. 1995 no.

adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow-acting anti-rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti-fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow- acting anti- rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti- fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications: